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BACKGROUND/OBJECTIVES: Delirium is common in
older adults, especially following hospitalization. Because
low vitamin D levels may be associated with increased delir-
ium risk, we aimed to determine the prognostic value of
blood vitamin D levels, extending our previous genetic ana-
lyses of this relationship.
DESIGN: Prospective cohort analysis.
SETTING: Community-based cohort study of adults from
22 cities across the United Kingdom (the UK Biobank).
PARTICIPANTS: Adults aged 60 and older by the end of
follow-up in the linked hospital inpatient admissions data,
up to 14 years after baseline (n = 351,320).
MEASUREMENTS: At baseline, serum vitamin D (25-OH-D)
levels were measured. We used time-to-event models to esti-
mate hazard ratios (HRs) and 95% confidence intervals
(CIs) for the association between vitamin D deficiency and
incident hospital-diagnosed delirium, adjusted for age, sex,
assessment month, assessment center, and ethnicity. We
performed Mendelian randomization genetic analysis in
European participants to further investigate vitamin D and
delirium risk.
RESULTS: A total of 3,634 (1.03%) participants had at
least one incident hospital-diagnosed delirium episode. Vita-
min D deficiency (<25 nmol/L) predicted a large incidence
in delirium (HR = 2.49; 95% CI = 2.24–2.76; P = 3*10−68,
compared with >50 nmol/L). Increased risk was not limited
to the deficient group: insufficient levels (25–50 nmol/L)
were also at increased risk (HR = 1.38; 95% CI = 1.28–1.49;
P = 4*10−18). The association was independent of calcium
levels, hospital-diagnosed fractures, dementia, and other rel-
evant cofactors. In genetic analysis, participants carrying
more vitamin D–increasing variants had a reduced likeli-
hood of incident delirium diagnosis (HR = .80 per standard
deviation increase in genetically instrumented vitamin D:
.73–.87; P = 2*10−7).
CONCLUSION: Progressively lower vitamin D levels
predicted increased risks of incident hospital-diagnosed
delirium, and genetic evidence supports a shared causal
pathway. Because low vitamin D levels are simple to detect
and inexpensive and safe to correct, an intervention trial to
confirm these results is urgently needed. J Am Geriatr Soc
00:1-8, 2020.
Keywords: delirium; vitamin D; risk factor; biomarker;
genetic
Delirium is an acute fluctuating change in cognitionassociated with inattention, disorganized thinking, or
altered level of consciousness, and it is common among hos-
pitalized older adults.1 It is potentially preventable and often
underrecognized in clinical practice,2 affecting 23% of acute
hospital admissions in adults,3 with considerable economic
and societal costs.4 Diagnosis rates in the community are
much lower (1%–2%).5 Causes of delirium are multifactorial
involving both underlying or predisposing (e.g., dementia,
advanced age) and precipitating factors, often acute events
(e.g., hospitalization, surgery, anesthesia, infection), with
inflammation, polypharmacy, constipation, catheterization,
environment, pain, and stroke also implicated.6
There is increasing interest in the role of vitamin D in
delirium and dementia, with a meta-analysis demonstra-
ting a correlation between low vitamin D and reduced
From the *Epidemiology & Public Health Group, University of Exeter,
Exeter, UK; †UConn Center on Aging, University of Connecticut,
Farmington, Connecticut; ‡Healthcare for Older People, Royal Devon and
Exeter NHS Foundation Trust, Exeter, UK; §Exeter Diabetes Group
(ExCEED), College of Medicine and Health, University of Exeter, Exeter,
UK; and the ¶MRC Integrative Epidemiology Unit, University of Bristol,
Bristol, UK.
Address correspondence to *Luke C. Pilling, PhD, Epidemiology & Public
Health Group, University of Exeter Medical School, College House (1.09),
St. Luke’s campus, Exeter, EX1 2LU, UK. E-mail: l.pilling@exeter.ac.uk.
Twitter: @lcpilling
DOI: 10.1111/jgs.16853
JAGS 00:1-8, 2020
© 2020 The Authors
Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society. 0002-8614/20/$15.00
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
cognition.7 Nevertheless, most of the studies included were
observational, and this effect was not replicated in interven-
tional studies with supplementation of vitamin D.7 A fur-
ther systematic review indicated a potential link between
low levels of vitamin D and the development of dementia.8
In our previous genetics study using Mendelian randomiza-
tion methods, we found evidence for a causal link between
lower vitamin D levels and higher risks of incident episodes
of delirium in hospital inpatient records in the United King-
dom (UK) Biobank. However, serum vitamin D levels were
not available at the time.9 Here we build on this work by
combining serum vitamin D levels, genetic information, and
four additional years of hospital inpatient follow-up to fur-
ther investigate this relationship.
In this study we aimed to estimate the association
between serum vitamin D levels and risk of incident
hospital-diagnosed delirium in a large community volunteer
sample. Although delirium is underdiagnosed in the hospi-
tal setting,2 previous work showed that delirium diagnoses
made in the hospital setting are accurate with a high level
of specificity.10 We also aimed to extend our previous
genetic analysis9 with the increased numbers of incident
delirium cases now available in the UK Biobank (n = 3,634
up from 544 in our previous work).
METHODS
The UK Biobank recruited 503,325 community-based vol-
unteers aged 40 to 70 between 2006 and 2010 from across
the United Kingdom.11 Data collected at the baseline assess-
ment included extensive questionnaires on demographic,
health, and lifestyle information. Anthropometric measures
were also taken, in addition to blood samples for future
biochemical and genetic analysis. Ethical approval for the
UK Biobank study was obtained from the North West
Multi-Centre Research Ethics Committee.
Serum Vitamin D
Serum 25-hydroxyvitamin D (25[OH]D, a proxy for vita-
min D levels) measurement (in nanomole per liter) was per-
formed by the immunoassay analyzer DiaSorin Liaison XL,
with data on 448,376 participants at baseline passing the
quality control procedures applied by the UK Biobank cen-
tral team12 (see the UK Biobank report for sensitivity,
interassay variability, and other information13).
We performed exploratory analysis on the following
potential vitamin D covariates: age, sex, self-reported eth-
nicity (split into six groups: White, Asian, Black, Other,
Mixed, or Missing), assessment month (season), and assess-
ment center (see Supplementary Methods S1 for details).
We adjusted for these covariates in all analyses.
Participants were split into three groups of vitamin D
levels according to the UK National Institute for Health
and Care Excellence (NICE) guidelines for the management
of vitamin D deficiency or insufficiency in adults14: deficient
for vitamin D if serum 25[OH]D levels are less than
25 nmol/L; insufficient vitamin D if serum 25(OH)D levels
are in the range of 25 to 50 nmol/L; and vitamin D levels
sufficient if serum 25(OH)D levels are above 50 nmol/L.
Delirium Diagnosis
Follow-up disease ascertainment from hospital admissions
records was available up to 14 years after assessment (end-
ing March 2020: data from Wales or Scotland were cen-
sored to February 29, 2016, and October 31, 2016,
respectively). A total of 270,299 of the 351,320 participants
(76.9%) included in this analysis had at least one hospital
admission after the baseline assessment. Diagnosis of delir-
ium was ascertained using International Diagnosis of
Diseases, Tenth Revision (ICD-10) code F05 (see Supple-
mentary Table S1 for all ICD-10 codes used in this analy-
sis). Due to the rarity of delirium diagnoses before age 605
(of the 3,634 participants with a hospital diagnosis of del-
irium, only 44 occurred before the age of 60), and that del-
irium in younger groups may have different etiology,
participants were excluded if they did not reach age 60 by
the date of censoring. Participants with a previous delirium
diagnosis at baseline (n = 45) were excluded. In the primary
analysis, no other exclusions were made. See Supplementary
Methods S1 for details on sensitivity analyses such as the
effect of exclusions (e.g., bone fractures).
Analysis of Vitamin D Association with Incident
Delirium
A total of 351,320 participants aged 60 and older at any
time during follow-up had sufficient data for analysis of vita-
min D and risk of incident delirium. Stata v.15.1 was used
for analysis. Cox proportional hazards regression models
estimated the association between vitamin D and incident
delirium, with adjustment for age, sex, assessment center,
assessment month, and self-reported ethnicity (see Supple-
mentary Methods for details). Visual inspection of Kaplan-
Meier plots and application of the Stata function estat phtest
detail to estimate Schoenfeld residuals were used to test for
violations of the proportional hazards assumption.
To model the nonlinear effect of vitamin D (nmol/L) on
rate of incident delirium diagnosis from Cox proportional
hazards regression models, we used the natural polynomial
smoothing spline function in R (v.4.0.2) package pspline
(v.1.0–18) and package survival (v.3.1–12). We used
default options for the smoothing parameters (modifying
these did not meaningfully affect the results).
Genetic Data
Genotyping and quality control were performed centrally by
the UK Biobank team.15 In brief, directly genotyped genetic
variants (n = 805,426) are available in 488,377 UK Biobank
participants, from two almost identical platforms sharing
more than 95% of variants: the Affymetrix Axiom UKB
array (in 438,427 participants) and the Affymetrix
UKBiLEVE array (in 49,950 participants). Genotype imputa-
tion was successful in 487,442 participants and increased the
number of genetic variants to approximately 96 million.15
Mendelian Randomization Analysis
Mendelian randomization (MR) analyses are used to deter-
mine whether an association between a risk factor
(e.g., vitamin D) and an outcome (e.g., delirium) may share
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a causal pathway. If individuals carrying more vitamin
D–increasing genetic variants have greater risk of delirium,
this supports the hypothesis of a shared causal pathway.
We previously applied these methods to an earlier version
of the UK Biobank data9 and here extend the analysis using
the longer follow-up now available (n = 3,405 delirium
cases, up from 544 in our previous work). Briefly, known
genetic variants associated with circulating 25[OH]D con-
centration were extracted from a large meta-analysis by
Jiang et al.16 that was independent of the UK Biobank
cohort. R (v.4.0.2) packages MendelianRandomization
(v.0.4.2) and RadialMR (v.0.4)17 were used. See Supple-
mentary Methods S1 for details.
RESULTS
We analyzed 351,320 UK Biobank participants who reached
age 60 before the end of the follow-up period and had com-
plete data (end March 2020; see Methods for details and
Supplementary Figure S1 for cohort flowchart). There were
3,634 (1.0%) participants with an incident delirium diagno-
sis in the hospital admissions data (Table 1).
We observed significant variation in vitamin D associated
with season (highest average levels recorded in August, lowest
in February: Supplementary Table S2 and Supplementary
Figure S2), assessment center (highest average levels recorded
in Cardiff, lowest in Glasgow; Supplementary Table S3), and
self-reported ethnicity (highest average levels in participants
reporting White ethnicity, lowest in those reporting any Asian
ethnicity; Supplementary Tables S4 and S5).
Vitamin D Deficiency Is Associated with Increased Risk
of Incident Delirium
We estimated the effect of serum vitamin D (nmol/L) on
rates of incident delirium diagnosis in Cox proportional
hazards regression models adjusted for age, sex, assessment
center, assessment month, and self-reported ethnicity, first
using a smoothing spline parameter to model continuous
and nonlinear effects: decreasing vitamin D was signifi-
cantly associated with risk of incident delirium (spline
P = 1.8*10−32), with risk progressively increasing below
approximately 75 nmol/L (Figure 1A).
Participants with deficient vitamin D levels (<25 nmol/L)
at the baseline assessment were at increased risk for incident
delirium (hazard ratio [HR] = 2.49; 95% confidence interval
[CI] = 2.25–2.76; P = 3*10−68) compared with those with
sufficient levels (≥50 nmol/L) in Cox proportional hazards
regression models adjusted for age, sex, assessment center,
assessment month, and self-reported ethnicity (Figure 1B).
Participants with insufficient levels were also at increased risk
(HR = 1.38; 95% CI = 1.28–1.49; P = 4*10−18).
In sex-stratified analysis, the effect of vitamin D defi-
ciency on risk of incident delirium was similar in men com-
pared with women (n = 164,288 men; HR = 2.51; 95% CI =
2.19–2.88; P = 3*10−39; n = 187,032 women; HR = 2.50;
95% CI = 2.14–2.92; P = 7*10−31), and there was no signifi-
cant interaction (P > .05).
We repeated the analysis only in the 335,517 partici-
pants (96%) who self-reported as White because individuals
of other ethnic groups are known to have lower vitamin D
levels while retaining the same level of bioavailable
vitamin D.20 The association between vitamin D deficiency
and incident delirium was very similar to the overall esti-
mate (HR = 2.58; 95% CI = 2.32–2.87; P = 7*10−70), and
there was no significant interaction (P > .05). Due to low
numbers of non-White participants (Table 1), analysis of
other ethnic groups was underpowered.
Sensitivity Analyses
In sensitivity analyses using Fine and Gray competing risks
regression, accounting for mortality as the competing risk
(23,584 of 351,320 participants died during follow-up), the
results remained consistent (deficient sub HR = 2.33; 95%
Table 1. Summary Statistics of 351,320 UK Biobank
Participants Eligible for Primary Analysis
Mean (SD) Min, Max
Age at baseline, y 60.39
(5.76)
47.06, 73.89
Age at end of follow-up or death, y 70.95
(5.71)
60.00, 86.28
Vitamin D at baseline, nmol/L 49.45
(20.93)
10, 335
Time to first delirium episode, y
(n = 3,634)
8.63 (2.25) .11, 12.84
Time to death, y (n = 23,584) 7.22 (3.07) .01, 13.06
N %a
Sex, women 187,032 53.24
Vitamin D, categories
Sufficient (>50 nmol/L) 162,514 46.26
Insufficient (25–50 nmol/L) 145,890 41.53
Deficient (<25 nmol/L) 42,916 12.22
Self-reported ethnicityb
White 335,517 95.5
Asian 6,135 1.8
Black 4,121 1.2
Other 2,486 .7
Mixed 1,469 .4
Prefer not to answer/Do not
know/Missing
1,592 .5
Highest education level attainedb
None 70,843 20.4
CSEs/GCSEs/O-levels 56,432 16.3
A-levels/NVQ/HND/HNC 59,282 17.1
Professional qualification (e.g.,
nursing, teaching)
53,392 15.4
College or university degree 107,108 30.9
Smoking status
Never 185,203 53.0
Former 131,260 37.6
Current 33,053 9.5
Died during follow-up 23,584 6.7
Delirium during follow-up 3,634 1.0
Any recorded hospital admission
during follow-up
270,299 76.9
Genetically European, with
vitamin D genetics
326,558 93.0
aPercentage of total participants without missing data for that phenotype.
bCombined groups; see Supplementary Information for more detailed
subgroups.
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CI = 2.10–2.58; P = 3*10−56; insufficient sub HR = 1.36;
95% CI = 1.26–1.47; P = 1*10−15).
The results were also consistent after multiple addi-
tional adjustments and exclusions were made (Table 2).
First was an adjustment for baseline smoking status and
educational attainment, a proxy for socioeconomic status
(vitamin D deficiency HR = 2.38; 95% CI = 2.14–2.64;
P = 2*10–59). Next was excluding 30,528 participants who
reported taking vitamin D supplements at baseline
(HR = 2.46; 95% CI = 2.21–2.74; P = 2*10−59). Next, we
additionally excluded 45,197 participants with hospital-
diagnosed bone fractures, chronic kidney disease (CKD),
dementia, liver disease (any), or Parkinson’s disease
(HR = 2.40; 95% CI = 2.00–2.89; P = 6*10−21). Similar
trends were seen for insufficient vitamin D levels (Table 2).
Vitamin D deficiency was associated with lower cal-
cium levels (coefficient −.020 mmol/L: −.019 to −.021; P =
4*10−281), but there was no linear association between cal-
cium levels and incident delirium diagnosis (HR per mmol/
L = .76; .52–1.10; P = .14). In nonlinear analysis, calcium
levels below 2.27 mmol/L or greater than 2.57 mmol/L were
associated with increased delirium risk using a smoothing
spline in Cox proportional hazards regression models
adjusted for age, sex, assessment center, assessment month,
and self-reported ethnicity (spline P = .03; Supplementary
Figure S4). The association between vitamin D and incident
delirium remained consistent after inclusion of the calcium
spline term in the model (vitamin D deficiency HR = 2.52;
95% CI = 2.24–2.83; P = 2*10−54).
To explore the known reduced sun exposure in frail, less
mobile individuals,21 we performed an analysis adjusted for
baseline frailty using the Frailty Index (FI) count of health def-
icits19 as a continuous covariate (n = 232,087 with complete
data); the estimate was modestly attenuated (HR = 2.16; 95%
CI = 1.89–2.47; P = 8*10−30) but not significantly different
(FI to vitamin D interaction P > .05) (Table 2).
We performed a single analysis with adjustment for
age, sex, assessment center, assessment month, self-reported
ethnicity, smoking status, educational attainment, calcium
levels, and FI, and excluded participants taking vitamin D
supplements, with hospital-diagnosed CKD, bone fractu-
res, dementia, liver disease, and Parkinson’s disease. The
association between vitamin D deficiency and incident delir-
ium remained consistent, albeit slightly attenuated, in Cox
proportional hazards regression models (n = 203,490 in
analysis; HR = 2.33; 95% CI = 1.88–2.89; P = 1*10−14;
Table 2). Participants with insufficient vitamin D levels were
also still at increased risk (HR = 1.31; 95% CI = 1.12–1.54;
P = 6*10−4).
Separately, we repeated the main analysis restricted to
those participants hospitalized during the follow-up period
(270,299 of 351,320 [76.9%]) and found that the associa-
tion between vitamin D deficiency and incident delirium
was similar to that in all participants (HR = 2.45; 95%
CI = 2.21–2.72; P = 8*10−66).
We also investigated whether the effect of vitamin D on
delirium depended on the delirium diagnosis resulting from a
surgical procedure (i.e., postoperative delirium only). Of 3,634
incident delirium cases, 1,473 (40.5%) were less than 72 hours
after a recorded hospital operation. The effect of vitamin D
deficiency on risk of incident delirium was consistent in an
analysis restricted to only postoperative cases (HR = 2.60;
95% CI = 2.22–3.06; P = 2*10−31) compared with an ana-
lysis restricted to those delirium diagnoses made where no sur-
gical procedure was recorded (delirium diagnoses = 2,161;
HR = 2.48; 95% CI = 2.17–2.82; P = 2*10−42).
Figure 1. Serum vitamin D and rates of incident delirium diag-
nosis. (A) Analysis of serum vitamin D (nmol/L) at baseline
and rates of incident delirium diagnosis using Cox proportional
hazards regression models adjusted for age, sex, assessment
center, assessment month, and self-reported ethnicity. A
smoothing spline function was applied to determine the
nonlinear effect of vitamin D on risk of incident delirium. The
x-axis is limited to 100 nmol/L for clarity; see Supplementary
Figure S3 for the unrestricted plot. (B) Unadjusted cumulative
event plot showing the proportion of the participants with a
diagnosis of delirium in the hospital in three groups, based on
baseline vitamin D sufficiency. R package survminer (v.0.4.8)
was used for plot B. CI, confidence interval.
4 PILLING ET AL. MONTH 2020-VOL. 00, NO. 00 JAGS
Vitamin D–Increasing Genetic Variants Are Associated
with Vitamin D Levels
A genetic risk score (GRS) for the number of vitamin
D–increasing variants each participant carried (weighted by the
published effect on vitamin D levels by Jiang et al16) were com-
puted in the 326,558 UK Biobank participants of European
ancestry who met the inclusion criteria for analysis (see
Methods). The GRS was strongly associated with serum vitamin
D (nmol/L) in linear regression models adjusted for age at vita-
min D assessment, sex, assessment center, assessment month,
and ethnicity (coefficient per standard deviation [SD] of
GRS = 3.37; 95% CI = 3.30–3.44; P = 1*10−2,029). The propor-
tion of the variation in vitamin D levels explained by the GRS
was 1.2%.
Calcium serum levels (μmol/L) were increased in individuals
with greater vitamin D GRS in linear regression models (coeffi-
cient per SD of GRS = 1.03; 95% CI = .68–1.37; P = 8*10−9).
However, this association lost significance when vitamin D was
included as a covariate (P = .3), suggesting the effect of vitamin
DGRS on calcium is via the effect on vitamin D.
Vitamin D–Increasing Genetic Variants Confirm
Reduced Likelihood of Incident Delirium Diagnosis
In MR analysis we found consistent evidence that higher
circulating vitamin D reduced the likelihood of incident
hospital diagnosis of delirium: the primary analysis was of
the MR-IVW penalized robust regression estimate (change
in log(HR) for delirium per log(nmol/L) vitamin D = −.48;
95% CI = −.66 to −.30; P = 2 × 10−7) using the six vitamin
D–associated variants from Jiang et al.16 (Table 3;
Figure 2A). The HR for delirium per SD genetically
instrumented log(vitamin D) is .799 (.735–.869). Sensitivity
analysis using Radial IVW (Figure 2B) or excluding the
large-effect single nucleotide polymorphism rs3755967
showed consistent effect size (Table 3), albeit attenuated sig-
nificance. We found no evidence for horizontal pleiotropy
Table 2. Vitamin D Deficiency Is Associated with Increased Rates of Incident Delirium
Model Vitamin D at baseline N N delirium Person-years HR (95% CI) P value
Model 1a Sufficient (>50 nmol/L) 162,514 1,484 1,728,790
Insufficient (25–50 nmol/L) 145,890 1,521 1,530,801 1.38 (1.28–1.49) 3.9*10–18
Deficient (<25 nmol/L) 42,916 629 440,778 2.49 (2.24–2.76) 3.4*10–68
+ Adjusted for education and smoking statusb 160,120 1,439 1,703,633
Insufficient (25–50 nmol/L) 143,609 1,472 1,507,279 1.37 (1.27–1.48) 1.3*10–16
Deficient (<25 nmol/L) 42,012 618 431,646 2.38 (2.14–2.64) 1.5*10–59
+ Excluding vitamin D supplements 140,274 1,246 1,491,439
Insufficient (25–50 nmol/L) 134,247 1,374 1,408,789 1.40 (1.29–1.52) 6.2*10–17
Deficient (<25 nmol/L) 40,692 598 418,019 2.46 (2.21–2.74) 2.1*10–59
+ Excluding comorbiditiesc 121,070 448 1,290,397
Insufficient (25–50 nmol/L) 115,022 473 1,209,590 1.32 (1.15–1.51) 4.1*10–5
Deficient (<25 nmol/L) 33,924 211 349,874 2.40 (2.00–2.89) 6.0*10–21
+ Adjusted for calciumb 110,391 406 1,176,061
Insufficient (25–50 nmol/L) 105,366 447 1,107,064 1.37 (1.19–1.58) 8.9*10–6
Deficient (<25 nmol/L) 31,194 197 321,497 2.45 (2.02–2.97) 2.6*10–20
+ Adjusted for Frailty Indexb 92,593 327 987,394
Insufficient (25–50 nmol/L) 86,341 348 907,548 1.31 (1.12–1.54) 6.1*10–4
Deficient (<25 nmol/L) 24,556 153 253,166 2.33 (1.88–2.89) 1.3*10–14
Abbreviations: CI, confidence intervals; HR, hazard ratio; N, sample size included in the model; N delirium, the number of incident delirium cases included in
the model.
aCox proportional hazards regression models adjusted for age, sex, assessment center, assessment month, and self-reported ethnicity.
bAt baseline assessment, participants with missing data excluded.
cEver diagnosed with bone fracture, chronic kidney disease, dementia, liver disease, or Parkinson’s disease in the hospital admissions data to March 2020,
prevalent or incident.
Table 3. Mendelian Randomization Estimates for the
Effect of Circulating Vitamin D on Delirium
Methoda Estimateb 95% CI P
IVW −.48 −.66 to −.30 2 × 10−7
Weighted median −.51 −1.02 to .00 .048
MR-Egger −.41 −.73 to −.10 .010
MR-Egger (intercept) .00 −.03 to .02 .755
Radial IVW −.48 −.76 to −.20 .001
Radial MR-Egger −.49 −1.01 to .04 .144
Radial MR-Egger
(intercept)
.01 −.87 to .90 .977
IVW (excluding
rs3755967)
−.41 −1.01 to .18 .173
aIVW, penalized robust inverse-variance weighted regression (assumes there
is no unbalanced horizontal pleiotropy); MR-Egger (intercept), like IVW
but the MR-Egger incept is not fixed, as deviation from the null is used to
test for possible horizontal pleiotropy; MR-Egger, penalized robust Egger
regression (assumes the genetic variants’ effect is not correlated with any
pleiotropic effect on the outcome); Radial IVW, Radial inverse-variance
weighted regression using modified second-order weights (no significant
outliers detected); Radial MR-Egger, intercept in unconstrained and
assumes that pleiotropic effects are independent of the Radial weights;
Weighted median, penalized weighted median estimate (assumes <50% of
the weight in the analysis comes from invalid instruments).
bln(HR) per ln(vitamin D). See Supplementary Table S6 for full details.
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with MR-Egger regression or Radial MR-Egger (intercept
P > .05; Table 3 and Figure 2C). See Supplementary
Table S6 for detailed results. In sensitivity analysis only
analyzing the cases in the updated hospital admissions
data since our previous publication9 (n = 2,861 between
February 2016 and March 2020), the association is consis-
tent in effect but attenuated in significance compared with
the analysis of diagnoses before February 2016 (n = 544;
see Supplementary Table S7 and Supplementary Figure S5).
DISCUSSION
In this large prospective study of 351,320 community-
based UK Biobank participants, aged 60 and older by the
end of the 14 years of follow-up, vitamin D levels
predicted increased risks of incident hospital-diagnosed
delirium. Genetic evidence supports a shared causal path-
way. The highest risk for delirium occurred in the vitamin
D deficient group (<25 nmol/L) compared with those with
sufficient levels (>50 nmol/L). Participants with vitamin D
insufficiency (25–50 nmol/L) also had an increased risk of
delirium at follow-up, with a smaller effect size,
suggesting a dose-response relationship. Genetic results
with a larger sample than we previously reported
(n = 3,405, up from 544) continue to support a causal
role overall, showing 20% reduction in delirium hazard
per SD of genetically instrumented vitamin D (limitations
discussed later). This research has important clinical rele-
vance and consequences; although delirium is an acute
diagnosis, it is known to increase the risk of dementia.22
Whether this is a causative role or an unmasking of
underlying cognitive vulnerability is unclear. However,
prevention of delirium can potentially delay irreversible
cognitive impairment.23 Additionally, economic analyses
in the United States have estimated that healthcare costs
for patients with delirium are 2.5 times greater than for
patients without delirium.24
This work is consistent with the results of a previous ret-
rospective cross-sectional study revealing lower levels of vita-
min D levels in patients with delirium in whom the levels
were checked.25 Low vitamin D levels were also more preva-
lent in patients with hip fractures and delirium (although the
numbers included were small and prone to confounding).26
A further retrospective cohort study of 4,508 participants
showed higher levels of hospital-acquired delirium in those
with lower vitamin D levels (checked before hospitalization).
However, the number of delirium cases was only 4%, and
they concluded that a future randomized controlled trial
would need to be conducted.27
The association between vitamin D and delirium is plau-
sible considering its hypothesized neuroprotective role in
preventing oxidative damage to nervous tissue and influence
on neuromediator synthesis.28 Vitamin D is also thought to
affect the inflammatory processes within the brain that
increase vulnerability to injury.29 Studies in rat models
showed vitamin D has a protective effect on neurons from
oxidative stress and the role of vitamin D in the growth and
protection of neurones.30 Vitamin D3 receptors were found
not only in brain neurons but also in the spinal cord and in
the peripheral nervous system.31 In addition, vitamin D recep-
tors were found in the hippocampus, an area of the brain
affected by Alzheimer’s disease and other neurodegenerative
conditions.32 Research also investigated the possible role of
vitamin D in the reduction of β-amyloid in mouse models.33
Vitamin D is also thought to impact systemic inflammation34
that during aging impacts comorbidities, frailty, and other
outcomes implicated in the pathogenesis of delirium.
Previous MR studies with vitamin D showed an associ-
ation between vitamin D–increasing alleles and Alzheimer’s
Figure 2. Vitamin D–increasing genetic variants associated
with reduced likelihood of incident delirium diagnosis. (A) Six
genetic variants are known to affect circulating 25(OH)D (vita-
min D) levels (effect shown on the x-axis). We determined the
association with risk of incident delirium for each genetic vari-
ant (shown on the y-axis). Mendelian randomization penalized
robust inverse-weighted regression (MR-IVW) results (includ-
ing 95% confidence intervals) show that genetic predisposition
to higher serum vitamin D is associated with reduced likelihood
of delirium diagnosis in the follow-up. (B) Radial IVW plot of
results using modified second-order weights (no significant out-
liers were detected). (C) Radial MR-Egger funnel plot showing
the regression intercept is not significantly different from the
null (no evidence of pleiotropy).
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disease.35 However, this evidence was inconclusive or tenta-
tive in a MR systematic review.36 Our previous article was,
to the best of our knowledge, the first report of MR to esti-
mate the relationship between vitamin D and delirium.9
The current article takes the previous work forward by
combining serum vitamin D levels and genetic information
to further investigate this relationship. The genetic variants
associated with vitamin D are known to influence its syn-
thesis and metabolism,16 suggesting a direct relationship
between vitamin D and delirium; our MR analysis results
are consistent with lack of pleiotropic effects (i.e., via other
pathways than vitamin D). The strength of the association
between vitamin D genetic variants and incident delirium is
attenuated when only using the “new” cases not included
in our previous report.9 Thus further work is required for
full confirmation.
Supporting a causal role for vitamin D in mental health
is a 2019 randomized clinical trial of vitamin D supplemen-
tation for 1 year in 200 older (aged ≥70 years) adults who
experienced a fall in the previous year; there were signifi-
cant improvements in mental health (the Mental Compo-
nent Summary of the Short Form Health Survey 36-item
patient health survey) in the groups achieving the highest
vitamin D levels at 12 months37 and strongest in those who
were deficient at baseline.
In this analysis we used vitamin D levels above
50 nmol/L to define “sufficient” levels, in line with the rele-
vant UK NICE guidelines.14 However, in our nonlinear anal-
ysis of vitamin D levels with risk of delirium (Figure 1A), the
lowest risk participants are those with levels of 75 nmol/L or
higher, a target recommended by the U.S. Endocrine Society
for treating and preventing vitamin D deficiency.38 Our data
suggest that 50 nmol/L may not be the optimum target for
delirium prevention, although more data are needed.
This study has some limitations. The diagnosis of delir-
ium for the purpose for this study was extracted from Hospi-
tal Episode Statistics data, and delirium is known to be
underdiagnosed in hospital settings.2 However, hospital diag-
nosis of delirium was shown to be more precise than in the
community, with a higher level of specificity.10 UK Biobank
reflects a generally younger age group who were fit and able
to attend assessment appointments and clinic visits. Although
studying a younger population may limit generalizability to
older adults, the mean age at end of follow-up was 71 years
(range = 60–86), meaning our ability to capture more typical
delirium cases seen in older hospitalized patients is improv-
ing. Remarkably, measured vitamin D levels are highly pre-
dictive of incident delirium up to 14 years before diagnosis,
showing it is a good biomarker.
A related point to consider is that previous hypotheses
suggested that the link between cognition and vitamin D
deficiency may just be a marker of increased frailty associ-
ated with cognitive decline and less sun exposure.21 We
included adjustments for season and month of assessment,
and test center as a measure to ameliorate the influence of
variable sun exposure. Frail individuals are at increased risk
of delirium,18 yet the association between vitamin D defi-
ciency and incident delirium was robust to adjustment for
the baseline FI (of course, frailty status can change, but this
observation means deficiency was not just a marker of base-
line frailty). Vitamin D deficiency can be associated with
other medical conditions that could increase the incidence
of delirium. We found the association to be robust to exclu-
sion of hospital-diagnosed bone fractures, CKD, and liver
disease. Taken together, our results, including genetic analy-
sis that is not susceptible to reverse causation and other tra-
ditional confounding factors, suggest that vitamin D
deficiency could be playing a more central role in delirium
susceptibility.
In conclusion, we demonstrated in this study that mea-
sured low vitamin D is associated with incident delirium,
with genetic evidence supporting a causal role. Vitamin D
deficiency is simple to rectify, at low cost and with minimal
side effects. This study provides a rationale for further inter-
ventional trials assessing the relationship between vitamin
D supplementation and cognition, with a focus on delirium
prevention. Our results suggest that older adults should be
routinely screened for vitamin D levels during general prac-
titioner visits to help ensure they are at sufficient levels in
the event that they require hospitalization where risk for
delirium increases considerably.
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